Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer

Sponsor
Centre Hospitalier Universitaire de Besancon
Study ID
NCT02842294
Status
Unknown

Conditions

  • Metastatic Colorectal Cancer
  • Quality of Life

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary aim of this french multicenter national study is to assess and compare time to quality of life score deterioration (targeted dimensions : global health, fatigue and emotional functionning of EORTC QLQC30 according to the first line chemotherapy associated with bevacizumab in metastatic colorectal patients.

Key Dates

First listed
Jul 22, 2016
Start date
May 31, 2013
Status verified
Jul 2016
Primary completion
Feb 28, 2017
Completion
Feb 28, 2018

Study Design

Enrollment
320 participants (estimated)

Arms

  • Arm: irinotecan based chemotherapy
    patients having a 1st line doublet chemotherapy including irinotecan
  • Arm: oxaliplatin based chemotherapy
    patients having a 1st line doublet chemotherapy including oxaliplatin
  • Arm: triplet chemotherapy
    patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy

Primary Outcome Measure

time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning) [ Time Frame: 1 year ]

Central Contacts

Related Studies